Literature DB >> 25781573

Immunotherapy: The development of immunotherapy in urothelial bladder cancer.

Tom Powles1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2015        PMID： 25781573     DOI： 10.1038/nrclinonc.2015.51

Source DB:  PubMed          Journal:  Nat Rev Clin Oncol        ISSN： 1759-4774            Impact factor:   66.675


× No keyword cloud information.
  9 in total

1.  Randomized phase III trial of high-dose-intensity methotrexate, vinblastine, doxorubicin, and cisplatin (MVAC) chemotherapy and recombinant human granulocyte colony-stimulating factor versus classic MVAC in advanced urothelial tract tumors: European Organization for Research and Treatment of Cancer Protocol no. 30924.

Authors:  C N Sternberg; P H de Mulder; J H Schornagel; C Théodore; S D Fossa; A T van Oosterom; F Witjes; M Spina; C J van Groeningen; C de Balincourt; L Collette
Journal:  J Clin Oncol       Date:  2001-05-15       Impact factor: 44.544

2.  Genetic basis for clinical response to CTLA-4 blockade in melanoma.

Authors:  Alexandra Snyder; Vladimir Makarov; Taha Merghoub; Jianda Yuan; Jedd D Wolchok; Timothy A Chan; Jesse M Zaretsky; Alexis Desrichard; Logan A Walsh; Michael A Postow; Phillip Wong; Teresa S Ho; Travis J Hollmann; Cameron Bruggeman; Kasthuri Kannan; Yanyun Li; Ceyhan Elipenahli; Cailian Liu; Christopher T Harbison; Lisu Wang; Antoni Ribas
Journal:  N Engl J Med       Date:  2014-11-19       Impact factor: 91.245

3.  Correlation of PD-L1 tumor expression and treatment outcomes in patients with renal cell carcinoma receiving sunitinib or pazopanib: results from COMPARZ, a randomized controlled trial.

Authors:  Toni K Choueiri; David J Figueroa; André P Fay; Sabina Signoretti; Yuan Liu; Robert Gagnon; Keith Deen; Christopher Carpenter; Peter Benson; Thai H Ho; Lini Pandite; Paul de Souza; Thomas Powles; Robert J Motzer
Journal:  Clin Cancer Res       Date:  2014-12-23       Impact factor: 12.531

4.  MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer.

Authors:  Thomas Powles; Joseph Paul Eder; Gregg D Fine; Fadi S Braiteh; Yohann Loriot; Cristina Cruz; Joaquim Bellmunt; Howard A Burris; Daniel P Petrylak; Siew-leng Teng; Xiaodong Shen; Zachary Boyd; Priti S Hegde; Daniel S Chen; Nicholas J Vogelzang
Journal:  Nature       Date:  2014-11-27       Impact factor: 49.962

5.  Association of PD-L1 expression on tumor-infiltrating mononuclear cells and overall survival in patients with urothelial carcinoma.

Authors:  J Bellmunt; S A Mullane; L Werner; A P Fay; M Callea; J J Leow; M E Taplin; T K Choueiri; F S Hodi; G J Freeman; S Signoretti
Journal:  Ann Oncol       Date:  2015-01-18       Impact factor: 32.976

Review 6.  Oncology meets immunology: the cancer-immunity cycle.

Authors:  Daniel S Chen; Ira Mellman
Journal:  Immunity       Date:  2013-07-25       Impact factor: 31.745

7.  Nivolumab plus ipilimumab in advanced melanoma.

Authors:  Jedd D Wolchok; Harriet Kluger; Margaret K Callahan; Michael A Postow; Naiyer A Rizvi; Alexander M Lesokhin; Neil H Segal; Charlotte E Ariyan; Ruth-Ann Gordon; Kathleen Reed; Matthew M Burke; Anne Caldwell; Stephanie A Kronenberg; Blessing U Agunwamba; Xiaoling Zhang; Israel Lowy; Hector David Inzunza; William Feely; Christine E Horak; Quan Hong; Alan J Korman; Jon M Wigginton; Ashok Gupta; Mario Sznol
Journal:  N Engl J Med       Date:  2013-06-02       Impact factor: 91.245

8.  EAU guidelines on muscle-invasive and metastatic bladder cancer: summary of the 2013 guidelines.

Authors:  J Alfred Witjes; Eva Compérat; Nigel C Cowan; Maria De Santis; Georgios Gakis; Thierry Lebret; Maria J Ribal; Antoine G Van der Heijden; Amir Sherif
Journal:  Eur Urol       Date:  2013-12-12       Impact factor: 20.096

9.  Comprehensive molecular characterization of urothelial bladder carcinoma.

Authors: 
Journal:  Nature       Date:  2014-01-29       Impact factor: 49.962
  9 in total
  4 in total

Review 1.  Coming of Age of Immunotherapy of Urothelial Cancer.

Authors:  Enrique Grande; Javier Molina-Cerrillo; Andrea Necchi
Journal:  Target Oncol       Date:  2021-03-12       Impact factor: 4.493

2.  Safety and Efficacy of Durvalumab (MEDI4736), an Anti-Programmed Cell Death Ligand-1 Immune Checkpoint Inhibitor, in Patients With Advanced Urothelial Bladder Cancer.

Authors:  Christophe Massard; Michael S Gordon; Sunil Sharma; Saeed Rafii; Zev A Wainberg; Jason Luke; Tyler J Curiel; Gerardo Colon-Otero; Omid Hamid; Rachel E Sanborn; Peter H O'Donnell; Alexandra Drakaki; Winston Tan; John F Kurland; Marlon C Rebelatto; Xiaoping Jin; John A Blake-Haskins; Ashok Gupta; Neil H Segal
Journal:  J Clin Oncol       Date:  2016-06-06       Impact factor: 44.544

Review 3.  Importance of immunopharmacogenomics in cancer treatment: Patient selection and monitoring for immune checkpoint antibodies.

Authors:  Noura Choudhury; Yusuke Nakamura
Journal:  Cancer Sci       Date:  2016-02       Impact factor: 6.716

4.  Development and validation of an intra-tumor heterogeneity-related signature to predict prognosis of bladder cancer: a study based on single-cell RNA-seq.

Authors:  Ranran Zhou; Jingjing Liang; Qi Chen; Hu Tian; Cheng Yang; Cundong Liu
Journal:  Aging (Albany NY)       Date:  2021-08-02       Impact factor: 5.682
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.